Biochemical and hemotologica changes against Doxorubicin Induced Toxicity in Rat

Document Type : Original Article


1 Biochemistry Department , Faculty of Veterinary Medicine, Banha University

2 Center for Genetic Engineering; Al-Azhar University ;Nasr City- Cairo; Egypt

3 Biochemistry department , Faculty of Veterinary Medicine, Banha University - Egypt


Doxorubicin is an anthracycline drug first extracted from Streptomyces peucetius var. caesius in the 1970’s. It used routinely as highly efficacious drug in many kinds of cancers. But its clinical usefulness is still restricted due to its specific toxicities. This study was designed to investigate doxorubicin-induced toxicity in albino rat model. Thirty male young adult Sprague Dawley rats were divided into Three groups. The first served as control group while second and third group treated with 2.5 and 5mg / kg /week.  Two hours post DOX administration rats from all the groups were killed, blood samples were drawn for hematological and biochemical changes. Data were analyzed using (SPSS, verson 22). Hematological parameters obtained from rats treated with Dox revealed that Dox doses induced decrease in RBCs Count, Hemoglobin (Hb) concentration and HCT % when compared with the corresponding values of control rats. Otherwise, WBC.s differential count including (lymphocyte, monocyte, neutrophil, monocyte as well as neutrophil) and platelets count showed a significant decrease (P<0.05) when compared with the values of control rats.  DOX doses for four weeks induced hepatic damage as reflected by significantly (p < 0.05) elevated serum ALT, TSB, and ALP enzymes activities when compared to control group. Albumin concentrations recorded a significant decrease. While serum urea concentration and creatinine levels were elevated (P<0.001) as compared with the values of control rats. The present study shed more of the light on the effect of Doxorubicin-induced toxicity in albino rat model. Showing several biochemical and hematological abnormal effects.


Main Subjects

[1] Zhon S, Palmeira CM, Wallace KB. Doxorubicin induced persistent oxidative stress to cardiac myocytes. Toxicol Lett. 2001;121:151–7. 
[2] Lenaz L, Page J, Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat Rev. 1976;3:111–20. 
[3] Myers CF, McGuire WP, Liss RH, Adriamycin: The role of lipid peroxidation in cardiac toxicity and tumor response.  Science.  1977; 197:165–7. 
[4] Bier CC, Jaenke RS, Function of myocardial mitochondria in the Adriamycin induced cardiomyopathy of rabbits. J Natl Cancer Inst. 1976;57:1091–94. 
[5] Geetha A, Devi CS, Effect of Doxorubicin on heart mitochondrial enzymes in rats: A protective role for alphatocopherol. Indian J Exp Biol. 1992;30:615–18. 
[6] Bristow MR, Sageman WS, Scott RH. Acute and chronic cardiovascular effects of doxorubicin in dog. J Cardiovasc Pharmacol. 1980; 2: 487–515. 
[7] Loren EW, Doxorubicin induces cardiomyocyte dysfunction via p38 MAP kinase dependent oxidative stress mechanism. Cancer Detect Prev. 2005; 29: 294–99. 
[8] Brown LA, Harris FL, Jones DP, Ascorbate deficiency and oxidative stress inalveolar type II cell. Am J Physiol. 1997;273:782–88. 
[9] Hanaa HA, Fathia M, Gamal AE, Senot HD, Cardioprotective activity of melatonin and its novel synthesized derivatives on doxorubicin induced cardiotoxicity. Bioorg Med Chem. 2005;13:1847–57. 
[10] Alessandra Y. Anthracycline-induced cardio toxicity: Posing the right questions to find the correct answers. Ann Biotechnol. 2018; 1(1): 1001-1003
[11] Bloom MW, Carine EH, Daniela C, Bonnie K, Anju N, Lea B, Hal S, Daniel JL, Mihai G, Alexander RL, and Javed B. MBA1Cancer Therapy-Related Cardiac Dysfunction and Heart Failure Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging. Circ Heart Fail. 2016 9(1): e002661.
[12] Athanasios K, Argyrios N, Evangelos R, Efsthathios K, Meletios AD and Ioannis P,  Cardio-oncology: A Focus on Cardiotoxicity. European Cardiology Review 2018;13(1):64–9.
[13] Abushoukab AI, Ammar I, Amr MA, Ahmed MA, Mohamed MA, Cardio protective mechanisms of phytochemicals against doxorubicin-induced cardio toxicity. Biomedicine & Pharmacotherapy 2017; 90: 935-46 DOI: 10.1016/j.biopha.2017.04.033
[14] Lip Shultz SE, Tracie LM, Rebecca ES, Stuart RL, Nader R, Lewis BS, Steven DC, Donna SN, Suzanne ED, Jacqueline MH, Barbara LA, Uma HA, Luis AC, Caroline L, Bruno M, Marshall AS, and Stephen ES, Changes in cardiac biomarkers during doxorubicin treatment of peadiatric patients with high-risk acute lymphoblastic leukemia: associations with long term echocardiographic outcomes. J Clin Oncol 2012;30(10):1042-49.
[15] Zilinyi R, Czompa A, Czegledi A, Gajtko A, Pituk D, Lekli I, Tosaki A, The Cardioprotective Effect of Metformin in Doxorubicin-Induced Cardiotoxicity: The Role of Autophagy. Molecules 2018;15;23(5): 1184-96.
[16] Ezquer F, Jaime G, Marcelo E, Christian C, Helio CS, and Sebastián DC, Mesenchymal stem cell therapy for doxorubicin cardiomyopathy: hopes and fears Stem Cell Research & Therapy. 2015; 6:116
[17] Oliveira MS, Melo MB, Carvalho JL, Melo IM, Lavor MS, Gomes DA, Doxorubicin cardiotoxicity and cardiac function improvement after stem cell therapy diagnosed by strain echocardiography. J Cancer Sci Ther.2013;5:52–7. doi:10.4172/1948-5956.1000184.
[18] Reitman & Frankel A, colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol. 1957 Jul;28(1):56-63.  doi: 10.1093/ ajcp/28.1.56.
[19] Moss DW. Alkaline phosphatase isoenzymes. Clin Chem. 1982;28:2007-2016
[20]Doumas, BT, Watson WA, and Biggs HG. Albumin standards and the measurement of serum albumin with bromcresol green. Clin Chim Acta. 1971 Jan;31(1):87-96.
[21] Balistreri WF, Shaw LM. liver function. In: Tietz, N.W, ed. Fundamentals of clinical chemistry. 3rd   ed. Philadelphia:WB Saunders: 1987 :729-761.
[22] Fawcett  JK, and Soctt JE,  A Rapid and Precise Method for The Determination  of  Urea. J Clin Pathol. 1960 Mar; 13(2): 156–159.
[23] Larsen K. Creatinine assay by a reaction-kinetic principle Clin Chim Acta. 1972 Oct;41:209-17. doi: 10.1016/0009-8981(72)90513-x.
[24] Armitage P, and Berry G. Statistical methods. In: Armitage, P; Berry, G (Geoffrey), editors Medical research. 3rd ed. London: Blackwell Scientific Publications: (1994); 12–48.
[25] Jing L, Wu Y, Wu J, Zhao J, Zuo D and Peng S, Peroxiredoxins are involved in metallothionein protection from doxorubicin cardiotoxicity. Eur J Pharmacol 2011; 659(2-3):224-32. DOI: 10.1016/j.ejphar.2011.03.031
[26] Hou XW, Jiang Y, Wang LF, Xu HY, Lin HM, He XY, He JJ and Zhang S, Protective role of granulocyte colony-stimulating factor against adriamycin induced cardiac, renal and hepatic toxicities. Toxicol Lett 2009; 187: 40-44.
[27] You JS, Pan TL, and Lee YS, Protective effects of Danshen (Salvia miltiorrhiza) on adriamycin-induced cardiac and hepatic toxicity in rats. Phytother Res. 2007; 21: 1146-52.
[28] Outomuro D, Grana DR, Azzato F and MileiJ: Adriamycin-induced myocardial toxicity: New solutions for an ole problems? Int J Cardiol. 2007; 117: 6-15.
[29] Piscitelli SC, Rodvold KA, Rushing DA and Tewksbury DA, Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small-cell lung cancer. Clin Pharmacol Ther. 1993; 53: 555-61.
[30] Swain SM, Whaley FS and Ewer MS, Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer. 2003; 97: 2869-79.
[31] King SL, Mohiuddin JJ and Dekaney CM, Paneth cells expand from newly created and preexisting cells during repair after doxorubicin-induced damage. Am J Physiol Gastrointest Liver Physiol. 2013; 305: G151-62.
[32] Tong N, Zhang J, Chen Y, Li Z, Luo Y, Zuo H and Zhao X, Berberine sensitizes mutliple human cancer cells to the anticancer effects of doxorubicin in vitro. Oncol Lett. 2012; 3: 1263-67.